Camber Launches Eltrombopag, AB Rated Generic to Promacta®
Pay as little as $0 for Camber's Eltrombopag with our Copay Program
Eltrombopag Tablets & Oral Suspension Now Available
Leaders in Product Approvals & Launches
62
Anticipated Launches in 2025
54
ANDA Approval Goal for 2025
35
New ANDA Filings in 2025
One Vision. One Mission. One Camber.
Generic Rx, Specialty, OTC
Camber is made up of three groups with one common goal: to be the best generics company in the industry. Camber Pharmaceuticals is rapidly growing and had an industry leading 45 product approvals in 2024. With the support of our parent company, Hetero, we are poised to have a record number of product approvals and launches in 2025.
News and Events
May 15, 2025
Piscataway, NJ, May 15, 2025 –Camber Pharmaceuticals is excited to announce the addition of Temozolomide Capsules, […]
May 14, 2025
Camber Pharmaceuticals is proud to announce the launch of Eltrombopag, the AB-rated generic for Promacta®. […]
May 6, 2025
Piscataway, NJ, May 6, 2025 –Camber Pharmaceuticals is excited to announce the addition of Eslicarbazepine […]
Camber Specialty Products
Camber Specialty will support the increasing demand for these products by providing hospitals, clinics, government facilities, and other institutional partners more high-quality generic choices.
Camber Consumer Care Over-the-Counter Products
We deliver high quality, over-the-counter medications you can trust. Our mission is to provide a focused and reliable supply of products to the marketplace, creating value for our partners and savings for the consumer.
Learn more
Vertical Advantage
Many of the generic medications Camber Pharmaceuticals offers in the United States are vertically integrated, from KSMs to APIs to FDFs. Camber products have consistent quality and reliable supply channels, helping reduce supply interruptions and mitigate risk.
Business Development
At Camber Pharmaceuticals, our goal is to bring affordable medicines to as many people as possible. As a company, we are continually interested in exploring business partnerships and licensing agreements with strategically aligned companies to support our diverse pipeline of generic products.
